Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age70+
SponsorXiaguang Duan

About this trial

This clinical trial investigates whether desflurane induces postoperative cognitive dysfunction (POCD) in elderly patients undergoing perioperative procedures by modulating Cdc42 and Clock proteins. The primary research questions are: (1) Does desflurane administration contribute to POCD in this patient population? and (2) Are alterations in Cdc42 and Clock protein levels associated with desflurane-induced POCD in elderly patients? To address these questions, elderly patients will be administered desflurane for anesthesia maintenance. Postoperative assessments will then compare blood levels of Cdc42 and Clock proteins, and examine related signaling pathways, between a control group and a POCD group.

Study participants will receive desflurane anesthesia maintained at a Bispectral Index (BIS) value of 40-60. Postoperative cognitive function will be assessed on the second day using the Montreal Cognitive Assessment (MoCA), and participants will be categorized into either a control group or a POCD group based on MoCA performance. Cognitive function and blood levels of Cdc42 and Clock proteins will be recorded. Furthermore, the study will also investigate associated signaling pathways.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age > 70 years

American Society of Anesthesiologists (ASA) physical status classification I-III

Scheduled to undergo elective surgery requiring general anesthesia with desflurane

Able and willing to provide voluntary written informed consent

Disqualifiers

Pre-existing diagnosis of dementia or any other neurodegenerative disease that could affect cognitive function

Preoperative Montreal Cognitive Assessment (MoCA) score < 20

History of severe psychiatric disorders, including psychosis, severe depression, or bipolar disorder

Unstable angina, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Desflurane Inhalation

    Drug

    Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.

  • mechanical ventilation (MV)

    Device

    Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: POCD groupExperimental treatment 2 interventions
Group B: ControlActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Montreal Cognitive Assessment (MoCA)

MoCA, is a rating system from 0 to 30, where 0 represents "no postoperative cognitive dysfunction" and 30 represents the worst possible postoperative cognitive dysfunction.

Time frame
At baseline (before therapy), at 2 days post-treatment

Secondary outcomes

1

Cell division control protein 42 homolog (Cdc42) and Circadian Locomotor Output Cycles Kaput(Clock)

The normal ranges of Cdc42 and Clock were consistent with preoperative levels. The higher the value, the greater the POCD, and the worse the outcome.

Time frame
At baseline (before therapy), at 2 days post-treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xiaguang Duan

Lead sponsor

Inner Mongolia Baogang Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: